Breast Cancer Res Treat (2012) 135:49–58 Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, dis- tribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Baak JP, Chin D, van Diest PJ, Ortiz R, Matze-Cok P, Bacus SS (1991) Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in parafﬁn-embedded invasive breast cancer. Lab Invest 64(2):215–223 2. Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357(1):39–51 3. Rodriguez-Pinilla SM, Jones RL, Lambros MB, Arriola E, Savage K, James M, Pinder SE, Reis-Filho JS (2007) MYC ampliﬁcation in breast cancer: a chromogenic in situ hybridisa- tion study. J Clin Pathol 60(9):1017–1023. doi:jcp.2006.043869 4. Cho EY, Choi YL, Han JJ, Kim KM, Oh YL (2008) Expression and ampliﬁcation of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathol Int 58(1):17–25 5. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez- Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A (2010) FGFR1 ampliﬁcation drives endocrine therapy resistance and is a thera- peutic target in breast cancer. Cancer Res 70(5):2085–2094. doi: 0008-5472.CAN-09-3746 6. Nielsen KV, Ejlertsen B, Moller S, Jorgensen JT, Knoop A, Knudsen H, Mouridsen HT (2008) The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 47(4):725–734 7. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28(12):2114–2122. doi:JCO.2009.25.5729 8. Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28(2):232–239. doi:JCO.2009.23.8162 9. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men: a population-based study. Cancer 101(1):51–57. doi:10.1002/cncr.20312 10. Muir D, Kanthan R, Kanthan SC (2003) Male versus female breast cancers. A population-based comparative immunohisto- chemical analysis. Arch Pathol Lab Med 127(1):36–41 11. Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, Guo M (2009) Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res 11(3):R28 12. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ (2012) Molecular subtyping of male breast cancer by immunohis- tochemistry. Mod Pathol 25(3):398–404. doi:10.1038/modpathol. 2011.174 13. Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, Gariboldi M, Pierotti MA, Daidone MG (2010) Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 127(3):601–610. doi:10.1007/s10549-010-1015-8 14. Johansson I, Nilsson C, Berglund P, Strand C, Jonsson G, Staaf J, Ringner M, Nevanlinna H, Barkardottir RB, Borg A, Olsson H, Luts L, Fjallskog ML, Hedenfalk I (2010) High-resolution 57 genomic proﬁling of male breast cancer reveals differences hid- den behind the similarities with female breast cancer. Breast Cancer Res Treat 129(3):747–760. doi:10.1007/s10549-010- 1262-8 15. Tommasi S, Mangia A, Iannelli G, Chiarappa P, Rossi E, Ottini L, Mottolese M, Zoli W, Zuffardi O, Paradiso A (2010) Gene copy number variation in male breast cancer by aCGH. Anal Cell Pathol 33(3):113–119 16. Moelans CB, de Weger RA, van Blokland MT, Ezendam C, Elshof S, Tilanus MG, van Diest PJ (2009) HER-2/neu ampliﬁ- cation testing in breast cancer by multiplex ligation-dependent probe ampliﬁcation in comparison with immunohistochemistry and in situ hybridization. Cell Oncol 31(1):1–10 17. Moelans CB, Verschuur-Maes AH, van Diest PJ (2011) Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 225(2):222–231. doi:10.1002/path.2930 18. Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ (2010) Molecular proﬁling of invasive breast cancer by mul- tiplex ligation-dependent probe ampliﬁcation-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 23(7): 1029–1039 19. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histo- pathology 19(5):403–410 20. van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, Kurver PH, Bellot SM, Fijnheer J, van Gorp LH, Kwee WS et al (1992) Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23(6):603–607 21. Moelans CB, de Weger RA, Ezendam C, van Diest PJ (2009) HER-2/neu ampliﬁcation testing in breast cancer by multiplex ligation-dependent probe ampliﬁcation: inﬂuence of manual- and laser microdissection. BMC Cancer 9:4 22. Bunyan DJ, Eccles DM, Sillibourne J, Wilkins E, Thomas NS, Shea-Simonds J, Duncan PJ, Curtis CE, Robinson DO, Harvey JF, Cross NC (2004) Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe ampliﬁcation. Br J Cancer 91(6):1155–1159 23. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G (2004) Prognostic relevance of gene ampliﬁcations and coampliﬁcations in breast cancer. Cancer Res 64(23):8534–8540 24. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C (2000) Relating genotype and phenotype in breast cancer: an analysis of the prognostic signiﬁcance of ampliﬁcation at eight different genes or loci and of p53 mutations. Cancer Res 60(4):1077–1083 25. Moelans CB, de Weger RA, van Diest PJ (2010) Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-depen- dent probe ampliﬁcation. Breast Cancer Res Treat 120(1):1–7. doi:10.1007/s10549-009-0539-2 26. Moelans CB, de Weger RA, van Diest PJ (2010) Chromosome 17 polysomy without HER2 ampliﬁcation does not predict response to lapatinib in metastatic breast cancer–letter. Clin Cancer Res 16(24):6177 27. Moelans CB, van Diest PJ (2011) Re: how do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear. J Natl Cancer Inst 103(8):698–699 28. Moelans CB, Reis-Filho JS, van Diest PJ (2011) Implications of rarity of chromosome 17 polysomy in breast cancer. Lancet Oncol 12(12):1087–1089. doi:S1470-2045(11)70234-0 123